Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

AIM-AF: A Physician Survey in the United States and Europe.

Publication ,  Journal Article
Camm, AJ; Blomström-Lundqvist, C; Boriani, G; Goette, A; Kowey, PR; Merino, JL; Piccini, JP; Saksena, S; Reiffel, JA
Published in: J Am Heart Assoc
March 15, 2022

Background Guideline recommendations are the accepted reference for selection of therapies for rhythm control of atrial fibrillation (AF). This study was designed to understand physicians' treatment practices and adherence to guidelines. Methods and Results The AIM-AF (Antiarrhythmic Medication for Atrial Fibrillation) study was an online survey of clinical cardiologists and electrophysiologists that was conducted in the United States and Europe (N=629). Respondents actively treated ≥30 patients with AF who received drug therapy, and had received or were referred for ablation every 3 months. The survey comprised 96 questions on physician demographics, AF types, and treatment practices. Overall, 54% of respondents considered guidelines to be the most important nonpatient factor influencing treatment choice. Across most queried comorbidities, amiodarone was selected by 60% to 80% of respondents. Other nonadherent usage included sotalol by 21% in patients with renal impairment; dofetilide initiation (16%, United States only) outside of hospital; class Ic agents by 6% in coronary artery disease; and dronedarone by 8% in patients with heart failure with reduced ejection fraction. Additionally, rhythm control strategies were frequently chosen in asymptomatic AF (antiarrhythmic drugs [AADs], 35%; ablation, 8%) and subclinical AF (AADs, 38%; ablation, 13%). Despite guideline algorithms emphasizing safety first, efficacy (48%) was selected as the most important consideration for AAD choice, followed by safety (34%). Conclusions Despite surveyed clinicians recognizing the importance of guidelines, nonadherence was frequently observed. While deviation may be reasonable in selected patients, in general, nonadherence has the potential to compromise patient safety. These findings highlight an underappreciation of the safe use of AADs, emphasizing the need for interventions to support optimal AAD selection.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

March 15, 2022

Volume

11

Issue

6

Start / End Page

e023838

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Surveys and Questionnaires
  • Physicians
  • Humans
  • Atrial Fibrillation
  • Anti-Arrhythmia Agents
  • Amiodarone
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Camm, A. J., Blomström-Lundqvist, C., Boriani, G., Goette, A., Kowey, P. R., Merino, J. L., … Reiffel, J. A. (2022). AIM-AF: A Physician Survey in the United States and Europe. J Am Heart Assoc, 11(6), e023838. https://doi.org/10.1161/JAHA.121.023838
Camm, A John, Carina Blomström-Lundqvist, Giuseppe Boriani, Andreas Goette, Peter R. Kowey, Jose L. Merino, Jonathan P. Piccini, Sanjeev Saksena, and James A. Reiffel. “AIM-AF: A Physician Survey in the United States and Europe.J Am Heart Assoc 11, no. 6 (March 15, 2022): e023838. https://doi.org/10.1161/JAHA.121.023838.
Camm AJ, Blomström-Lundqvist C, Boriani G, Goette A, Kowey PR, Merino JL, et al. AIM-AF: A Physician Survey in the United States and Europe. J Am Heart Assoc. 2022 Mar 15;11(6):e023838.
Camm, A. John, et al. “AIM-AF: A Physician Survey in the United States and Europe.J Am Heart Assoc, vol. 11, no. 6, Mar. 2022, p. e023838. Pubmed, doi:10.1161/JAHA.121.023838.
Camm AJ, Blomström-Lundqvist C, Boriani G, Goette A, Kowey PR, Merino JL, Piccini JP, Saksena S, Reiffel JA. AIM-AF: A Physician Survey in the United States and Europe. J Am Heart Assoc. 2022 Mar 15;11(6):e023838.
Journal cover image

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

March 15, 2022

Volume

11

Issue

6

Start / End Page

e023838

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Surveys and Questionnaires
  • Physicians
  • Humans
  • Atrial Fibrillation
  • Anti-Arrhythmia Agents
  • Amiodarone
  • 1102 Cardiorespiratory Medicine and Haematology